Associate Professor Anders Gabrielsen
Ribocure Pharmaceuticals, Gothenburg (Sweden)
Member of:
/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
First-in-human study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of RBD4059, a GalNAc-siRNA drug targeting coagulation factor XI (FXI), in healthy subjects
Event: ESC Congress 2024
Topic: Anticoagulants
Session: Biotherapies in cardiovascular disease: from bench to bedside
